NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

患者腫瘤組織移植 (PDX) 模式的全球市場 (2021年∼2028年)

Global Patient Derived Xenograft (PDX) Models Market - 2021-2028

出版商 DataM Intelligence 商品編碼 1008538
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
患者腫瘤組織移植 (PDX) 模式的全球市場 (2021年∼2028年) Global Patient Derived Xenograft (PDX) Models Market - 2021-2028
出版日期: 2021年06月01日內容資訊: 英文 180 Pages
簡介

作為全球患者腫瘤組織移植 (PDX) 模式市場的主要驅動力是對個性化醫療不斷增長的需求、公共和私營部門對癌症研究的持續支持以及製藥行業的研發 (R&D)。這包括擴大活動和增加對人性化 PDX 模型的需求。按類型來看,未來小鼠模型有望大幅增長,按腫瘤類型劃分,呼吸道腫瘤佔據很大佔有率。按地區劃分,北美國家所佔佔有率最大,預計將繼續快速增長。

本報告提供全球患者腫瘤組織移植 (PDX) 模式的市場相關分析,提供市場規模趨勢預測,及各類型·各腫瘤類型·各用途·各終端用戶·各地區的詳細趨勢,主要的推動及阻礙市場要素,主要企業的簡介等相關調查。

目錄

第1章 全球患者腫瘤組織移植 (PDX) 模式市場:分析方法·範圍

第2章 全球患者腫瘤組織移植 (PDX) 模式市場:市場定義和概要

第3章 全球患者腫瘤組織移植 (PDX) 模式市場:摘要整理

第4章 全球患者腫瘤組織移植 (PDX) 模式市場:市場動態

  • 對市場的影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球患者腫瘤組織移植 (PDX) 模式市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球患者腫瘤組織移植 (PDX) 模式市場:新型冠狀病毒感染疾病 (COVID-19)的分析

  • COVID-19對市場的影響分析
    • COVID-19前的市場方案
    • 目前市場方案
    • COVID-19後的市場方案
  • COVID-19疫情下的價格趨勢
  • 需求與供給的變動階段
  • 政府在COVID-19疫情下的市場相關措施
  • 各製造公司的策略展開情形
  • 結論

第7章 全球患者腫瘤組織移植 (PDX) 模式市場:各類型

  • 簡介
    • 市場規模的分析與與前一年同期相比成長率 (YoY):各類型
    • 市場向心力指數:各類型
  • 小鼠模型
    • 簡介
    • 市場規模 (以金額為準,2018年∼2028年)·與前一年同期相比成長率 (YoY) (2020年∼2028年)
  • 老鼠模型

第8章 全球患者腫瘤組織移植 (PDX) 模式市場:各腫瘤類型

  • 簡介
    • 市場規模的分析與與前一年同期相比成長率 (YoY):各腫瘤類型
    • 市場向心力指數:各腫瘤類型
  • 消化管腫瘤模式
  • 婦產科腫瘤模式
  • 呼吸系統腫瘤模式
  • 其他腫瘤模式

第9章 全球患者腫瘤組織移植 (PDX) 模式市場:各用途

  • 簡介
    • 市場規模的分析與與前一年同期相比成長率 (YoY):各用途
    • 市場向心力指數:各用途
  • 醫藥品的前臨床開發
  • 生物標記分析
  • 癌症基礎調查

第10章 全球患者腫瘤組織移植 (PDX) 模式市場:各終端用戶

  • 簡介
    • 市場規模的分析與與前一年同期相比成長率 (YoY):各終端用戶
    • 市場向心力指數:各終端用戶
  • 製藥·生物科技企業
  • CRO (醫藥品臨床研究委外機構)
  • 教育·研究機關
  • 其他

第11章 全球患者腫瘤組織移植 (PDX) 模式市場:各地區

  • 簡介
    • 市場規模和與前一年同期相比成長率 (YoY):各地區
    • 市場向心力指數:各地區
  • 北美
    • 簡介
    • 域內市場固有趨勢
    • 市場規模·與前一年同期相比成長率 (YoY):各類型
    • 市場規模·與前一年同期相比成長率 (YoY):各腫瘤類型
    • 市場規模·與前一年同期相比成長率 (YoY):各用途
    • 市場規模·與前一年同期相比成長率 (YoY):各終端用戶
    • 市場規模·與前一年同期相比成長率 (YoY):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第12章 全球患者腫瘤組織移植 (PDX) 模式市場:競爭情形

  • 主要趨勢與策略
  • 企業佔有率分析
  • 產品的互相比較
  • 值得注意的企業
  • 有顛覆性技術的企業
  • Start-Ups企業

第13章 全球患者腫瘤組織移植 (PDX) 模式市場:企業簡介

  • Charles River Laboratories
    • 企業概要
    • 產品的組合/概要
    • 近幾年趨勢
    • 財務分析:概要
  • Envigo
  • JSR Corporation(Crown Bioscience Inc.)
  • Champions Oncology, Inc.
  • EPO Berlin-Buch GmbH
  • Hera BioLabs
  • Horizon Discovery Group plc
  • WuXi AppTec
  • BEIJING IDMO Co. Ltd.
  • Shanghai ChemPartner Co., Ltd..

第14章 關於DataM Intelligence

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The global patient derived xenograft (PDX) models market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Patient-derived xenografts (PDX) are models of cancer where the cells or tissue of a patient's tumor are embedded into an immune deficient or humanized mouse. PDX models resemble human tumor biology allowing for natural cancer sequence and offer the most translational research model for estimating efficacy.

Market Dynamics

The major factors driving the growth of this market are the growing demand for personalized medicine, continuous support for cancer research from the public and private sectors, and growth in the number of R&D activities in the pharmaceutical industry.

The growing demand for personalized medicine will drive the market growth

Personalized medicine is developing tailored medicines to provide individualized medication and care based on individual and genetic variations. These medicines are produced through the use of animal models. In this process, immunodeficient models are revamped with human tissues, and the disease expressed is recorded. It is followed by employing the model with drugs/gene therapeutics to find the most suitable medication, thus generating suitable or personalized medicines.

The development of therapeutics for key disorders such as cancer has attracted significant attention. Presently, cancer is a significant burden on the healthcare sector across the world. As per the data published by GLOBOCAN in 2020, it is expected that 19.3 million cases and 10 million cancer deaths occurred in 2020. In vivo and in vitro strategies are being developed to fight the rising prevalence of cancer and offer efficient treatments to patients. A significant advancement in this regard is the development of PDX models, as they have imminent high power for the efficacy of standard and novel anti-cancer therapeutics. Owing to this convenience, these models are frequently being used in preclinical studies.

Rising demand for humanized PDX models is driving the market growth

Immunodeficient mice are now reconstituted with bone marrow or peripheral blood cells and patient tumor implants to generate humanized xenograft models. These models present a valuable stage to study the participation of xenogeneic immune cells in the overall anti-tumor immunity. They also help study immunotherapy drugs aimed at mobilizing the effector arm of the immune system. However, in humanized xenografts, there is a potential risk of graft versus host disease. Therefore the limitation can be mitigated by keeping the experimental setup and analysis to a reasonable time frame of 6-10 weeks.

However, these models are not fitting for evaluating stroma-tumor interactions, majorly accountable for tumor growth and progression in a patient. Humanized PDX models help surmount these issues and are gaining demand in the market.

For instance, in September 2018, JSR Corporation company announced addition of PDX models of prostate cancer to its product portfolio.

High cost of personalized PDX models will hamper the market growth in the forecast period

Howevwer, for building the personalized PDX models, a patient's tumor is embedded and grown in various immunocompromised models. It is then stored, fragmented, and inserted again in a more extensive set of models treated with different drugs and drug combinations. After analyzing the cost of building and maintaining these models, coupled with the necessity of expensive drugs in these models, PDX experiments will cost thousands of dollars, even in the case of a particular patient. Moreover, using PDX models in government-funded research can also be cost-prohibitive. These factors are limiting the adoption of PDX models market across the globe.

Industry Analysis

PEST Analysis:

COVID-19 Impact Analysis

The COVID-19 pandemic has impacted the healthcare systems globally and also has a notable impact on the market. PDX models market is negatively impacted by COVID 19 pandemic due to decreased productivity in life science organizations associated with country-wise lockdowns, the interruption of clinical trials, and decreased pharma R&D deals in therapeutic areas.

For instance, As per the GEP Worldwide, it is estimated that more than 1,200 clinical trials over the globe were interrupted by June 2020. Nearly 61% of clinical trials were disrupted due to the delay of patient enrolment. Trials including respiratory disease, ID/anti-infectives, oncology, and cardiovascular disease were the hard-hit during this time. The market is propelled to grow at a steady rate after the situation gets normal.

Segment Analysis

Mice model segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

The mice model are expected to account for the largest share of the market. Mice models are small animal models for several infectious disorders, including Zika virus, hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV), among others. Therefore certain mice models are widely used for various viral investigations in pre-clinical studies.

For instance, in March 2019, the National Institute of Allergy and Infectious Diseases funded projects to conduct detailed characterization, direct comparisons, and additional humanized immune system (HIS) mouse models. The increasing need to evaluate the outcomes of drugs on humans coupled with a growing focus on analyzing human-specific infections, treatments, and immune responses fosters the development and use of humanized mice models.

Major companies are concentrating on developing their product portfolios by new launches. For instance, in July 2019, Taconic Biosciences launched the first commercially available diet-induced NASH rodent model. This new model will keep researchers months of preparation and expedite the clinical development of NASH therapy to treat liver failure.

Thus, the mice model segment is expanding, increasing R&D activities in the pharmaceutical industry.

Respiratory tumor model segment are expected to dominate the patient derived xenograft (PDX) models market, by tumor type, during the forecast period

The respiratory tumor model segment is anticipated to grow at a faster pace in the forecast period. The key constituents contributing to the segment's growth include increasing research activities in oncology and the increasing focus of market players on generating lung cancer PDX models, and the increasing number of cancer cases.

As per WHO, cancer is the second principal cause of death globally and is accountable for 9.6 million deaths in 2018. Many companies focus on producing breakthrough products to tackle chronic diseases to keep their competitive edge and penetrate new regional markets. Additionally, funding for companies associated with cancer research is anticipated to boost the market.

Geographical Analysis

North America region holds the largest market share in the global Patient derived xenograft (PDX) models market

North America region dominates the global patient-derived xenograft (PDX) models market estimated for the largest market share in 2020, owing to a surge in funding and awareness among patients about personalized medication. Patient-derived tumor xenografts are perceived as very suitable preclinical cancer models. According to the American Cancer Society, there were 1,735,350 new cases of cancer diagnosed in the United States in 2018. Also, in 2018, the National Institute of Cancer expands the repository of cancer investigation models to incorporate more research models.

As per the American Cancer Society's estimation, the new lung cancer cases in the United States for 2018 were around 234,030, and about 154,050 deaths were expected due to lung cancer. In the United States, lung cancer survival has been improved, and the incidence of localized lung cancer has increased.

Market players are involved in product launch, product trials pipelines, product approvals and acquisitions. For instance, In November 2019, Envigo acquired the assets of the research models business unit of Horizon Discovery Group plc

Hence, the North American region is expected to grow faster due to rising preclinical activities by pharmaceutical companies and rising cancer research in this region.

Competitive Landscape

The patient derived xenograft (PDX) models market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Charles River Laboratories, Envigo, JSR Corporation (Crown Bioscience Inc.), Champions Oncology, Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, WuXi AppTec, BEIJING IDMO Co. Ltd., Shanghai ChemPartner Co., Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the patient derived xenograft (PDX) models market globally.

Patient Derived Xenograft (PDX) Models Market Key Companies to Watch

Charles River Laboratories

Overview: Charles River Laboratories International, Inc. is an American pharmaceutical company specializing in various preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical Device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry (for example, contract research organization services) and offers support in basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

Product Portfolio: The company offers research models & services, discovery services, preclinical cro services for safety assessment, and laboratory sciences among others.

Key Development: In 2019, Charles River Laboratories renewed its online Tumor Model Compendium by combining 79 new patient-derived xenografts, ten new cell line-derived xenografts, and 36 new cell line models for several cancer types including anal, colon, lung, and renal cancer, as well as leukemia and melanoma.

Why Purchase the Report?

  • Visualize the composition of the patient derived xenograft (PDX) models market segmentation by type, tumor type, application and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in patient derived xenograft (PDX) models market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of patient derived xenograft (PDX) models market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global patient derived xenograft (PDX) models market report would provide an access to an approx. 61 market data table, 52 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Patient Derived Xenograft (PDX) Models Market - By Type

  • Mice Model
  • Rats Model

Global Patient Derived Xenograft (PDX) Models Market - By Tumor Type

  • Gastrointestinal Tumor Model
  • Gynecological Tumor Model
  • Respiratory Tumor Model
  • Other Tumor Model

Global Patient Derived Xenograft (PDX) Models Market - By Application

  • Preclinical Drug Development
  • Biomarker Analysis
  • Basic Cancer Research

Global Patient Derived Xenograft (PDX) Models Market - By End User

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutions
  • Others

Global Patient Derived Xenograft (PDX) Models Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Patient Derived Xenograft (PDX) Models Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Patient Derived Xenograft (PDX) Models Market - Market Definition and Overview

3. Global Patient Derived Xenograft (PDX) Models Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Tumor Type
  • 3.3. Market Snippet by Application
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Global Patient Derived Xenograft (PDX) Models Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The growing demand for personalized medicine will drive the market growth
      • 4.1.1.2. Rising demand for humanized PDX models is driving the market growth
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of personalized PDX models will hamper the market growth in the forecast period
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Patient Derived Xenograft (PDX) Models Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Patient Derived Xenograft (PDX) Models Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Patient Derived Xenograft (PDX) Models Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Mice Model*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Rats Model

8. Global Patient Derived Xenograft (PDX) Models Market - By Tumor Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
    • 8.1.2. Market Attractiveness Index, By Tumor Type
  • 8.2. Gastrointestinal Tumor Model*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Gynecological Tumor Model
  • 8.4. Respiratory Tumor Model
  • 8.5. Other Tumor Model

9. Global Patient Derived Xenograft (PDX) Models Market - By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Preclinical Drug Development*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Biomarker Analysis
  • 9.4. Basic Cancer Research

10. Global Patient Derived Xenograft (PDX) Models Market - By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Pharmaceutical & Biotechnology Companies *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Contract Research Organizations (CROs)
  • 10.4. Academic & Research Institutions
  • 10.5. Others

11. Global Patient Derived Xenograft (PDX) Models Market - By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Global Patient Derived Xenograft (PDX) Models Market - Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. Key Companies to Watch
  • 12.5. Company with disruptive technology
  • 12.6. Start Up Companies

13. Global Patient Derived Xenograft (PDX) Models Market- Company Profiles

  • 13.1. Charles River Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Envigo
  • 13.3. JSR Corporation (Crown Bioscience Inc.)
  • 13.4. Champions Oncology, Inc.
  • 13.5. EPO Berlin-Buch GmbH
  • 13.6. Hera BioLabs
  • 13.7. Horizon Discovery Group plc
  • 13.8. WuXi AppTec
  • 13.9. BEIJING IDMO Co. Ltd.
  • 13.10. Shanghai ChemPartner Co., Ltd..

LIST NOT EXHAUSTIVE

14. Global Patient Derived Xenograft (PDX) Models Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us